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Abstract  
Immunotherapy, via intra-vesical instillations of BCG, is the therapy of choice for patients with high risk 
non-muscle invasive bladder cancer. The subsequent recruitment of lymphocytes and myeloid cells, as 
well as the release of cytokines and chemokines, is believed to induce a local immune response that 
eliminates these tumours, but the detailed mechanisms of action of this therapy are not well 
understood. Here, we have studied the phenotype and function of the responding lymphocyte 
populations as well as the spectrum of cytokines and chemokines produced in an in vitro model of 
human peripheral blood mononuclear cells (PBMCs) co-cultured with BCG. Natural Killer (NK) cell 
activation was a prominent feature of this immune response and we have studied the expansion of this 
lymphocyte population in detail. We show that, after BCG stimulation, CD56dim NK cells proliferate, 
upregulate CD56, but maintain the expression of CD16 and the ability to mediate ADCC. CD56bright NK 
cells also contribute to this expansion by increasing CD16 and KIR expression. These unconventional 
CD56bright cells efficiently degranulated against bladder cancer cells and the expansion of this population 
required the release of soluble factors by other immune cells in the context of BCG. Consistent with 
these in vitro data, a small, but significant increase in the intensity of CD16 expression was noted in 
peripheral blood CD56bright cells from bladder cancer patients undergoing BCG therapy, that was not 
observed in patients treated with mitomycin-C instillations. These observations suggest that activation of 
NK cells may be an important component of the anti-tumoral immune response triggered by BCG 
therapy in bladder cancer.  
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INTRODUCTION 
Bacille Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis used as the vaccine for 
tuberculosis, is well known to be a potent enhancer of the immune response. For example, mycobacteria 
are a key component of Freund’s adjuvant widely used in immunisation 1. The immuno-stimulatory 
properties of mycobacteria have also been exploited as an effective treatment for bladder cancer for 
several decades [reviewed in 2]. In fact, BCG instillation is considered the “gold-standard” treatment for 
non-muscle invasive bladder cancer (NMIBC) and has been demonstrated to be more effective than 
chemotherapy in these patients, showing statistically significant reduced recurrence, progression and 
mortality at 10 years. That 70% of patients respond to BCG suggests that the study of the mechanisms 
underlying the elimination of the tumours during BCG treatment could give more insight into how the 
immune system recognises tumours. Moreover, a better understanding of how this therapy works may 
aid in the identification of responder and non-responder patients at an early stage of therapy, when the 
optimal treatment strategy for each patient needs to be decided.  
 
Although several immune effectors, including cytotoxic T lymphocytes (CTLs), Natural Killer (NK) cells, 
monocytes and neutrophils have been suggested to be involved in the response generated after BCG 
instillation 3, 4, data from in vitro experiments and from murine models suggest that NK cells and Natural 
Killer T (NKT) cells might play key roles in the immune response against bladder cancer cells 5-11. NK cells 
are known to be crucial players in host pathogen interactions 12-15, however, it is also now appreciated 
that they comprise a heterogeneous population of effector cells whose response to a large variety of 
stimuli (viral infection, bacterial compounds, tumour transformation, etc.) depends on a complex array 
of receptor-ligand interactions and signalling events. Thus, to understand the NK cell response against 
tumours stimulated by BCG, it is necessary to dissect the contribution of distinct populations of these 
innate effector cells. CD56, an isoform of the human neural cell adhesion molecule (NCAM1), that is used 
as general marker for human NK cells 16, divides these lymphocytes into two populations. The majority of 
circulating NK cells (95%) have low expression of CD56 and are considered the mature cytotoxic NK cell 
subset. These CD56dim cells also express high levels of the low affinity FcγRIIIA receptor (CD16A) that 
mediates antibody-dependent cell-mediated cytotoxicity (ADCC) upon recognition of target cells 
opsonised with IgG. In contrast, the minority population of circulating CD56bright NK cells (5%) are 
generally considered more immature; they express little or no CD16 and respond better to soluble 
factors. These two subpopulations of NK cells, CD56bright and CD56dim, can be further distinguished by the 
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differential expression of other NK receptors such as Killer Immunoglobulin-like Receptors (KIRs), Natural 
Cytotoxicity Receptors (NCRs) and CD94/NKG2A so that, in general, the phenotype of the so called 
immature NK cells is CD56bright CD16lo/- CD94/NKG2Ahi KIR- while mature cytotoxic NK cells would be 
CD56dim CD16+ CD94/NKG2A+/- KIRhi 17, 18.  
 
Initially CD56bright NK cells were mainly thought of as cytokine-producing regulatory cells whilst the 
CD56dim subset were specialised for cytotoxicity. However, both NK cell subsets can produce large 
amounts of IFNγ, with the difference between them residing in the stimuli required to elicit their 
response. CD56bright NK cells proliferate and produce IFNγ in response to Dendritic cell (DC)-derived 
cytokines such as IL2, IL12, IL15 and IL18 19 while CD56dim NK cells secrete IFNγ after recognition of 
activating ligands on target cells 20. CD56bright and CD56dim NK cells also differ in their proliferative 
response to IL2, intrinsic cytotoxic capacity, NK receptor repertoire and adhesion molecule expression. 
We have previously reported that the recognition of bladder cancer cells by purified, IL2-activated NK 
cells is not affected by exposure to BCG but that co-culture with BCG and other lymphocytes did affect 
the NK response 11. We now report that one of the most prominent responses elicited by exposure of 
Peripheral Blood Mononuclear Cells (PBMCs) to BCG is the proliferation and activation of NK cells that 
become CD56bright while retaining many of the phenotypic and functional characteristics of mature 
CD56dim NK cells including a high capacity to degranulate against bladder cancer cells and to mediate 
ADCC. This process depends on the production of mainly innate cytokines in these cultures.  Analysis of 
the NK cell compartment in the peripheral blood of a small cohort of bladder cancer patients revealed 
that peaks of CD56bright NK cells expressing significantly increased amounts of CD16 at the cell surface can 
be observed in patients treated with BCG, but not with mitomycin C. These observations support the 
idea that NK cell activation triggered by exposure of infiltrating leukocytes to BCG is an important factor 
in the generation of an immune response against the tumour cells. 
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RESULTS 
PBMCs exposed to BCG expand a cytotoxic subpopulation of CD56bright NK cells 
PBMCs freshly isolated from healthy donors were incubated for a week in the presence or absence of 
BCG and then analysed by flow cytometry. The most striking change noted in these cultures was a 
dramatic increase in the mean fluorescence intensity (MFI) of CD56 in the NK cell population 
accompanied by an increase in the proportion of the CD3-CD56bright population (Figure 1A) that was 
consistently observed in PBMCs from multiple donors (Figure 1B). Next, the ability of the BCG-activated 
NK cells to respond against target cells and, in particular, against bladder cancer cell lines was evaluated 
in experiments where surface expression of LAMP-1 was assayed as a marker of degranulation. Both 
CD56bright and CD56dim NK cells responded to a classical NK target, the erythroleukaemia cell line K562, 
and against a range of bladder cancer cell lines with variable intensity (Figure 1C).  Notably, BCG-
stimulated CD56bright NK cells showed an increased ability to recognise bladder cancer cells and this 
degranulation capacity was higher than that of CD56dim NK cells exposed, or not, to BCG. The activating 
receptor NKG2D was important for the recognition of bladder cancer cells (Supplementary Figure 1), 
however, the contribution of this receptor to cytotoxicity was less pronounced for BCG-activated NK cells 
than for IL2-activated NK cells 11. Since CD56bright NK cells are a minority in peripheral blood, and often 
thought of as an immature subpopulation, this result raised several questions about the origin and 
functionality of these cells.  
Analysis of activation markers on both NK cell subpopulations revealed that CD56bright NK cells were 
activated in response to mycobacteria. A peak of high expression of the activation marker CD69 was 
observed after 3-4 days of co-culture between PBMCs and BCG (72±14% of the CD56bright cells were 
positive for CD69). The expression of CD25 (IL2Rα) increased starting day 4 until day 7 in nearly 100% of 
the population (95±2%) (Figure 1D). In contrast, the expression of activation markers by CD56dim NK cells 
in the culture was always lower than that observed for the CD56bright subset after BCG stimulation and 
only in a low percentage of cells (7% for CD69 at day 4; 27% for CD25, at day 7). 
CD56bright NK cells are, in general, a cytokine-secreting population19, with only a limited capacity to 
mediate natural cytotoxicity 21. Thus, in order to better understand the origin and the basis of these anti-
tumour CD56bright NK cells, the expansion of these populations of NK cells in the presence of BCG was 
further characterised. Proliferation experiments, using PBMCs labelled with CellTrace™ Violet stain 
revealed that CD56bright NK cells started proliferating on day 4 of the co-culture of PBMCs with BCG, while 
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no proliferating CD56dim NK cells were observed during the first week of co-culture in the presence of 
BCG (Figure 1E). In fact, the fraction of CD56dim cells decreased over this time and death of CD56dim NK 
cells could be observed from day 3 of the co-culture with BCG (data not shown and Supplementary 
Figure 2). Proliferation of CD3+ T cells and CD3+CD56+ was detected only after 6-7 days of co-culture 
(Figure 1F) suggesting that proliferation of a subpopulation of CD56bright NK cells with an increased 
tumour recognition capacity is a dominant feature of the early lymphocyte response to BCG. 
 
BCG-stimulated CD56bright NK cells have an intermediate phenotype between mature and immature NK 
cells 
The expression of other NK receptors on the BCG-activated CD56bright NK cell population was analysed by 
flow cytometry. Peripheral blood CD56bright cells usually express CD94, in association with NKG2A, while 
they are negative for CD16 and KIR (Supplementary Figure 3) 16, 17. BCG-activated CD56bright NK cells 
expressed CD94 but, interestingly, the fluorescence intensity for this receptor was higher in the BCG-
activated cells than in untreated CD56bright cells, and this was true at both days 3 (data not shown) and 7 
(Figure 2). In contrast to the typical phenotype of CD56bright cells in peripheral blood, which do not 
express KIR or CD16, ~25 and ~50% of the BCG-activated CD56bright population stained for KIR and for 
CD16 respectively and the fluorescence intensity of CD16 was higher than in the CD56dim cells. CD57, a 
marker associated with terminal stages of NK cell differentiation, was also expressed by the BCG-
activated population of CD56bright CD16+ NK cells but not by CD56bright from untreated cultures (Figure 2 
and Supplementary Figure 4 A-E). Although there is no relationship between any particular KIR and the 
expansion of the activated population, the percentage of KIR+ cells was increased among BCG-stimulated 
CD56bright cells that also expressed CD16 and CD57, compared to the KIR+ expression on the whole 
population of activated CD56bright (supplementary Figure 4D, E). It is also interesting to note that the 
percentage of CD57+ cells was increased in CD16+ vs CD16- CD56bright cells. Thus, these detailed studies of 
the BCG-activated CD56bright NK cells, led to the conclusion that they were not “classical” CD56bright NK 
cells, but rather activated NK cells. Thus for the rest of this paper, although we will continue to use the 
nomenclature CD56bright and dim, to compare NK cells expressing high vs low amounts of CD56, we need 
to clarify that “BCG-stimulated CD56bright NK cells” are not the usual CD56 bright subset, usually found in a 
low percentage peripheral blood, but instead represent a newly activated NK cell population. Indeed, the 
observed phenotype, especially their newly acquired degranulation capacity, implied that BCG exposure 
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generated an anti-tumoral subset of CD56bright NK cells, many of which express high levels of CD16 and 
can co-express CD57 and KIR. 
 
A majority of BCG-stimulated CD56bright NK cells derive mainly from CD56dim NK cells  
To define more precisely the origin of the cytotoxic CD56bright NK cell population that expanded after BCG 
exposure, experiments were carried out using PBMC preparations from which one of the CD56-
expressing NK subpopulations had been depleted. PBMCs from healthy donors were labelled with CD3 
and CD56 antibodies and PBMCs lacking only the CD56bright or the CD56dim subpopulation were obtained 
by cell sorting. Then, co-cultures with BCG were set up, either using unfractionated PBMCs or the sorted 
PBMCs lacking one CD56 subpopulation (Figure 3A). After one week in culture, these PBMC populations 
were analysed by flow cytometry (Figure 3B). As expected, exposure of whole PBMCs to BCG, led to a 
significant expansion of CD56bright NK cells. Strikingly, a very similar subpopulation was also observed in 
the co-culture initiated with PBMCs containing only CD56dim NK cells, suggesting that many of the BCG-
stimulated cytotoxic CD56bright population actually derived from CD56dim cells. This CD56bright population 
also showed an increased expression of CD16, KIR, CD57 and CD94, demonstrating that the CD56dim 
population of NK cells can upregulate the expression of CD56 at the cell surface while maintaining 
mature-phenotype receptor expression and functional capacities. Interestingly, CD56bright NK cells 
expressing CD16 and increased levels of CD94 could also be generated from CD56dim-depleted PBMCs 
exposed to BCG, suggesting that differentiation of the CD56bright NK subset after exposure to BCG also 
contributed to the observed expansion of phenotypically mature and cytotoxic CD56bright NK cells. 
 
BCG-stimulated CD56bright NK cells contain cytotoxic granules and mediate ADCC 
The function of the CD56bright NK cell population that expanded after co-culture with BCG was studied 
next. CD56dim NK cells are usually preloaded with granzyme B and perforin-containing granules. When 
PBMCs were cultured in medium alone, perforin and granzyme expression decreased (data not shown). 
In contrast, after co-culture with BCG, the CD56bright NK cells contained significantly more perforin and 
granzyme B, consistent with their cytotoxic capacities (Figure 4A, B). There was no statistically significant 
increase in perforin and granzyme B-containing granules of CD56dim NK cells. Since CD56bright NK cells are 
usually efficient cytokine producers 13, the ability of BCG-stimulated NK cells to secrete IFNγ after target-
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cell recognition was also analysed (Figure 4C). IFNγ production by CD56bright NK cells was increased at day 
3 of BCG co-culture, when compared with the unstimulated CD56bright NK cells, however, at day 7, no 
IFNγ production was triggered by bladder cancer cells under any condition. This result indicates that, 
before the burst of NK cell proliferation and the increase in surface CD56 expression, each subpopulation 
still displayed their main functional capacity: i.e. CD56bright being secretory and CD56dim cytotoxic. CD56 
upregulation was evident from days 4-5 of the co-culture (data not shown). By day 7, when the CD56bright 
NK cell subpopulation was mainly composed of CD56dim cells with increased levels of cell surface CD56, 
the main functional characteristic of this population was cytotoxicity. 
Consistent with the expression of CD16 on the BCG-stimulated CD56bright cells (Figure 2), these effector 
cells could also mediate ADCC against Raji cells that had been previously sensitised with Rituximab 
(Figure 4D). Also the loss of CD16 in BCG-treated CD56dim NK cells resulted in a decrease of ADCC activity. 
All these data are consistent with the idea that the majority of these CD56bright cells originate from 
CD56dim NK cells which have upregulated cell surface expression of the CD56 molecule and undergone 
intense cell proliferation. A transformation that likely reflects alterations in the maturation and 
activation status of these NK cells. 
 
Expansion and priming of BCG-stimulated CD56bright NK cells depends on soluble factors 
The expansion of BCG-stimulated CD56bright NK cells primed to degranulate in response to cancer cells 
could depend on direct interactions with BCG, cross-talk with other cellular populations from peripheral 
blood or soluble factors secreted within the co-culture. Our previous experiments argued against the 
first possibility 11, thus whether the priming and/or the expansion of CD56bright population depended on 
the presence of soluble factors was tested. Supernatants obtained after one week of PBMC and BCG co-
culture were prepared and used to stimulate a new culture of PBMCs without BCG addition. In this 
culture, a marked expansion of the CD56bright NK cells (Figure 5A), as well as the potentiation of the 
degranulation capacity against bladder tumour cells (Figure 5B) were also observed. However, only 
modest increases in the degranulation capacity of CD56dim NK cells in these cultures were observed. 
These data indicate that soluble factors are involved in the expansion of BCG-activated CD56bright NK 
cells. To confirm this hypothesis and check whether direct contact with other immune populations was 
needed to generate the population of activated CD56bright, experiments where purified CD56bright or 
CD56dim NK cells were separated by a transwell from a PBMC/BCG co-culture were carried out. Under 
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these conditions, CD56dim cells acquired the CD56bright phenotype (Figure 5C), accompanied by expression 
of CD16 (Figure 5D) and other markers usually present in the CD56dim population, such as KIR and CD57 
(data not shown), even though they only had contact with the supernatants generated in PBMCs co-
cultured with BCG. Interestingly, the degree of CD56 acquisition varied slightly between different donors, 
probably reflecting variation in the time required by NK cells from each donor to achieve full activation.   
 
Next, the amounts of an extensive panel of cytokines and chemokines were measured at different time 
points in supernatants from in vitro co-cultures of BCG and PBMCs of three healthy donors (Figure 6). In 
parallel, the expansion and degranulation capacity of CD56bright NK cells after BCG exposure were also 
evaluated (Supplementary Figure 5). These three donors showed similar patterns and levels of 
production of soluble factors, suggesting only limited variation in the response to BCG between donors. 
IL2 was found at a similar concentration in both untreated and BCG-treated co-cultures, and may be 
responsible for the survival of T and NK cells in the culture. IL4, IL8, IL9, IL22, IL23 and MIG were also 
found in both conditions, although the amounts of these cytokines were higher in the BCG-treated 
cultures. The levels of IL9, IL22 and IL23 (from day 1) and MIG (from day 3) increased during the week in 
co-culture with BCG, although some of these cytokines could also be detected at low concentrations in 
PBMC cultures not exposed to BCG. 
IL6, IL12p70, TNFα were found at constant concentrations in the supernatants of the BCG-treated PBMCs 
from the first day of co-culture, but were undetectable in the untreated cultures. Many of these 
cytokines have been found in urine collected from patients immediately after the BCG instillations 22. 
High amounts of IL10 and IL1β were detected on day 1 in BCG containing co-cultures (and undetectable 
in the absence of BCG), but then decreased over time. Increasing concentrations of MIP-1β and RANTES 
(from day 1) and IFNγ and IL17a (from day 3) were detected in the presence of BCG but not found in 
untreated cultures. Increasing concentrations of IP10 were found in both conditions, suggesting that 
myeloid-lineage cells may be activated in these cultures. 
In general, the pattern of cytokines found in the co-cultures during the first days agrees with the initial 
pro-inflammatory response detected in patient samples collected immediately after the instillations 
where a high degree of acute inflammation was accompanied by elevated levels of TNFα, IL6, IL1β and 
IL8 [22-24 and references therein]. However, our new data reveal a marked increase in the release of a 
range of other innate and pathogen-induced soluble factors, in the days following the first 48 hours after 
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exposure to BCG. These data suggest that a second wave of factors, including IFN, IL17a, IL22, IL23 and 
MIP-1 , might contribute to modulate the immune response and help in the elimination of the tumour.  
 
NK cell phenotype in BCG-treated bladder cancer patients  
In light of the above in vitro experiments, it was of interest to analyse whether related changes could be 
detected in the immune response of patients in vivo. For this purpose, immune changes in PBMCs of a 
cohort of 10 bladder cancer patients treated with BCG were followed for 18 months. Samples were 
obtained either 7 days or 3 months after each instillation, to focus on monitoring the long-lasting 
features of the response (Figure 7A). As a control, 7 bladder cancer patients receiving mitomycin C 
instillations, with a different schedule of treatment, were also included in the study. NK cells were 
studied in these blood samples (Figure 7B). This approach was limited by the fact that NK cells that had 
re-circulated through the bladder would only be a fraction of peripheral blood NK cells. Nevertheless, a 
higher percentage of CD56bright NK cells was present on average in BCG-treated patients compared to 
mitomycin C-treated patients, which was closer to the proportion (5%) observed in healthy donors 
(Figure 7C). NK cells from peripheral blood of the BCG-treated patients also showed an increase in the 
MFI of CD16 when comparing the samples obtained at time 0 with those obtained one year later (Figure 
7D). This increased CD16 expression was statistically significant for CD56bright NK cells from BCG-treated 
patients, but not for the CD56dim subpopulation. No statistically significant changes for either NK cell 
subpopulation was noted in mitomycin C-treated patients after 3 months. This observation is consistent 
with the data obtained in our in vitro experiments. Altogether, these results suggest that a larger cohort 
including a panel of NK cell markers should be studied to establish the link between levels of CD56 and 
response to treatment. Furthermore, since the changes in PBMCs are likely to be mild, a detailed study 
of the immune cells found in urine might provide additional useful information. 
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DISCUSSION 
Here, we report that the exposure of PBMCs to BCG results in the activation and proliferation of an 
unconventional cytotoxic subpopulation of CD56bright NK cells that maintain expression of receptors such 
as CD16 and KIR. The expansion of these cells depends on soluble factors, mainly innate cytokines. We 
show that, after one week of co-culture with BCG, these activated CD56bright NK cells have an unusual 
CD3- CD56bright CD94bright CD16+ KIR2D+ phenotype and have become specialised to mediate cytotoxicity. 
We also report that, in a small cohort of bladder cancer patients treated with BCG, a small, but 
significant, increase in numbers of CD56bright CD16+ NK cells circulating in peripheral blood was observed. 
While the generation of a CD56bright NK cell subset in response to live BCG or other bacterial compounds 
has been described previously 5, 25, 26, in this paper we report for the first time that the NK cells expanded 
on co-culture with BCG are mainly derived from the CD56dim subpopulation, although CD56bright cells also 
can increase the MFI of other NK receptors. These NK cells have upregulated CD56 to become CD56bright 
effectors and are activated (as shown by the expression of CD25 and CD69), proliferate vigorously and 
degranulate against bladder cancer cells. Moreover, they maintain many of the phenotypic and 
functional characteristics of a mature NK subpopulation, including the high expression of several NK 
receptors and the capacity to mediate ADCC. In contrast to what is known about NK cells responding to 
viruses, BCG-stimulated CD56bright cells do not seem to correspond to a population that can be defined by 
the expression of single or a limited number of cell surface receptors. For example, HCMV infection is 
associated with the expansion of a late differentiated CD57+ NKG2C+ population27, 28, that is usually 
CD16low, while a CD56dim NKG2D+ NKG2A+ CD57- KIR- early differentiated subpopulation expands after 
EBV infections 29, 30. In contrast, BCG exposure clearly activates a wider range of NK cells including 
CD56dim CD94+ KIR- and CD56dim CD57+ KIR+ NK cells (Supplementary Figure 4 D,E). Thus these data on 
changes in NK cells induced by BCG exposure provide a clear example of NK cell plasticity. These 
observations of the retention of CD16 expression and ADCC function are also in marked contrast to the 
matrix metalloprotease mediated shedding that produces a loss of CD16, that generally accompanies 
CD56 upregulation after NK stimulation by target cells and cytokines 31, 32. 
It is also interesting to note that sorted CD56bright NK cells can also contribute to the expansion of 
CD16+CD94+KIR+ NK cells on co-culture with BCG. Human NK cells develop from CD34+ hematopoietic 
stem cells (HSC) that acquire different receptors sequentially, allowing characterisation of several 
intermediate immature stages 33, 34. In a late stage, CD56bright cells (stage 4), characterised by high 
expression of CD94 and the absence of CD16, have been proposed to become mature CD56dim cells 
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(stage 5), acquiring CD16 and KIR expression and losing CD94 and CD117 in this process 19, 35, 36, although 
the exact sequence of events during these later stages of NK cell differentiation is still debated 32. To 
date, it has proven difficult to drive the differentiation of purified CD56bright stage 4 NK cells towards later 
stages of NK cell development in vitro. Our data have shown that BCG treatment of PBMC cultures can 
also provoke CD56bright CD16- NK cells to upregulate CD16 and CD94 and transition towards a CD56bright 
cytotoxic population with a reduced ability to produce IFN-γ that could correspond to an intermediate 
between the defined differentiation stages 4 and 5 of NK cell differentiation 36, 37. Double-positive 
CD56bright CD16+ cells are found in small numbers in peripheral blood and have been observed in other 
situations such as ageing 38, 39, infection 26 and transplantation 40. CD56bright NK cells expressing CD16 have 
also been described in metastatic lymph nodes in melanoma 41 and breast cancer 42 and are a subject of 
active research. The data reported here suggest that the cytotoxic CD56bright CD16+ cells that expand 
after BCG stimulation could represent an alternative pathway of NK cell maturation from CD56dim 
precursors, perhaps related to IL12 and IL15-stimulated NK cells, which also retain the CD16+ phenotype 
26 and emphasise that there may be considerably more plasticity in the pathways of NK cell maturation 
than currently appreciated. 
 
In this paper we also demonstrate that the soluble factors released after BCG stimulation of 
PBMCs are sufficient to drive the expansion and priming of the anti-tumoral CD56bright NK cells. Our 
analysis of cytokines present in the in vitro co-cultures of PBMCs and BCG revealed interesting features 
about the cellular populations that could be involved in the response, since several of the factors are 
most likely produced by myeloid cells and other innate immune cells. The co-culture of PBMCs with BCG 
is enough to initiate a strong cytokine response with high amounts of a range of soluble factors, 
including TNFα, increasing amounts of monokines, such as RANTES, MIP-1β and IP10, as well as an initial 
pulse of IL10 that subsequently declines and practically disappears. T cells are probably responsible for 
the secretion of IL2, detected both in the presence and absence of BCG and, thus, it seems reasonable to 
assume that both T cells and antigen-presenting cells probably participate in the secretion of cytokines 
that drive the NK expansion and differentiation in the culture. 
 
Finally, we have looked in vivo for correlates of our in vitro observations. We have evaluated the 
presence of CD3-CD56bright CD16+ effector NK cells in blood samples from bladder cancer patients treated 
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with either BCG instillation or mitomycin C. These analyses are difficult because detection of small 
populations of effector cells in peripheral blood is a very indirect manner of evaluating the local response 
in the bladder and is further complicated by the usually low percentage of circulating CD3-CD56bright cells. 
Nevertheless, we could observe a clear pattern of increased CD56 expression in 6 out of 10 BCG-treated 
patients that was not noted in mitomycin C-treated patients. Importantly, CD16 expression was brighter 
on CD56bright NK cells from bladder cancer patients that had undergone BCG treatment compared to NK 
cells from mitomycin C-treated patients, again confirming the in vitro data. These initial data should be 
further confirmed by analysing PBMCs from a larger cohort as well as different time points. However, 
since our analyses of patients at least partially validate the in vitro model, it also seems plausible that 
analysis of the immune response activated in the bladder might provide more direct and thus stronger 
data than that obtained from studies on peripheral blood. For this reason we are currently recruiting 
patients for a new study characterising the immune cells shed into urine, and thus susceptible to analysis 
by flow cytometry, with the idea that this will allow exploration of whether the CD56bright CD16+ effector 
NK cell population is recruited to, or expanded in, cancerous bladder tissue. 
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MATERIALS AND METHODS 
Reagents and antibodies 
Directly-labelled antibodies for analysis of blood lymphocytes were from Biolegend and Immunotools 
(Supplementary Table 1). Biotinylated anti-human granzyme B antibody was purchased from MABTECH 
and biotinylated anti-human perforin from Ancell; APC-Cy7 conjugated streptavidin from Biolegend. PE-
conjugated anti-human IFNγ antibody was from BD Pharmingen. Secondary FITC- and PE-conjugated 
anti-mouse Ig antibodies were from DakoCytomation. Blocking antibodies, specific for anti-human 
NKG2D (clone 149810) and NKp46/NCR1 (clone 195314) were from R&D. 
BCG Tice strain (from Merck Canada Inc.) was used. Aliquots of reconstituted BCG were prepared in 
RPMI 10% DMSO and stored at -20⁰C. The viability of the bacteria was not affected by this process. 
 
Cell lines and peripheral blood mononuclear cell culture 
Culture of the bladder cancer cell lines UM-UC-3, RT-112, J82, T24, SW780 and RT4 used in this study has 
been described previously 11.  
PBMCs from healthy volunteer buffy coats [(Regional Transfusion Centre, Madrid), were isolated by 
centrifugation on Ficoll-HyPaque and cultured in complete (4 mM L-glutamine, 0.1 mM nonessential 
amino acids, 1 mM sodium pyruvate, 100U/ml penicillin, 100U/ml streptomycin, 10mM Hepes, 50µM β-
mercaptoethanol) RPMI-1640 medium (Lonza) supplemented with 5% FBS, 5% male AB human serum, 
(Biowest). K562 cells were used for functional assays and grown in complete RPMI-1640 medium (Lonza) 
supplemented with 10% FBS. 
PBMCs were incubated in 24-well plates at 106 cells/ml with or without BCG at a 1:50 ratio (viable 
bacteria to PBMC). At the days indicated for each experiment, cells in suspension were recovered from 
the co-culture, centrifuged, analysed by flow cytometry or used as effector cells in functional 
experiments.  In experiments using BCG-conditioned medium, supernatants were recovered at day 7, 
centrifuged at 200 x g to eliminate cells and at 13000 x g to eliminate bacteria. Supernatants were added 
to a fresh PBMC culture, diluting 1:2 with fresh complete RPMI supplemented with 5% FBS, 5% male AB 
human serum. Cells were incubated for a further week. 
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Degranulation assays and ADCC 
Untreated or BCG-treated PBMCs were co-cultured with target cells, pretreated with HP1F7 antibody to 
block MHC-I 43, for 2 hours at an E:T ratio of 5:1 [i.e. 1:2 NK:target ratio. NK cells would represent around 
10% of total PBMCs. Although some donor-to-donor variation was encountered, the difference between 
treated and untreated was not significant, thus not affecting the comparison]. In experiments where NK 
cell receptors were blocked, monoclonal antibodies were included in the medium to a final 
concentration of 5 µg/ml for 20 min, prior to co-incubation with target cells. K562 cells were used as 
positive control targets for NK degranulation. For ADCC, Raji cells, pretreated or not with Rituximab 
(RTX), were used as targets in 2 hour experiments at an E:T ratio of 5:1 [i.e. 1:2 NK:target ratio]. Surface 
expression of LAMP1 (CD107a) was analysed by flow cytometry. Statistical analyses were performed 
using the Prism 6 software. 
 
Flow cytometry 
Cells were incubated with the appropriate primary antibodies, followed by either streptavidin-APC-Cy7, 
or PE- or FITC-labelled F(ab’)2 fragments of goat anti-mouse Ig (Dako), or directly with the conjugated 
antibodies for surface markers. For intracellular staining (granzyme B, perforin, IFNγ), cells were fixed 
with 2% para-formaldehyde at room temperature (RT) for 10 min and permeabilised with 0.2% saponin 
at RT for 10 min. For identification of cell death, cells were stained, washed and incubated with Annexin 
V-PE (Immunostep) and 7-AAD (Sigma), following the manufacturer’s instructions, and then analysed by 
flow cytometry. Samples were analysed using BD FACSCalibur (Becton Dickinson), Gallios Flow Cytometer 
or Cytomics FC 500 (Beckman Coulter). Analysis of the experiments was performed using Kaluza or 
FlowJo softwares.  
 
Proliferation assays 
PBMCs were incubated with 2 μM CellTrace™ Violet stain (Molecular Probes) for 20 min at 37⁰C 5% CO2. 
RPMI 10% FBS was then added for 5 min and the cells were washed once with complete medium and 
resuspended again before plating in 24-well plates in the presence or absence of BCG. At different times 
(days 1-7), cells were recovered and analysed by flow cytometry. 
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Measurement of IFNγ production 
Untreated or BCG-treated PBMCs were co-cultured with target cells for 6 hours at 37⁰C 5% CO2 at a 
PBMC:target ratio of 5:1 [i.e. 1:2 NK:target ratio]. After 1 hour of co-incubation, monensin was added to 
a final concentration of 2.5 μM. After 6 hours, cells were recovered, fixed, permeabilised and 
intracellular IFNγ was analysed by flow cytometry. 
 
Cell sorting experiments 
PBMCs were stained in sterile conditions with directly conjugated anti-CD3-FITC and anti-CD56-APC 
antibodies and, after washing and filtering, they were processed through a HIPERSORT MoFlow XDP 
sorter cytometer to eliminate either CD56bright or CD56dim NK subpopulations. The composition of the 
sorted populations was assessed by flow cytometry and PBMC containing only one of the NK cell subsets 
were analysed in the experiments. 
 
Cytokine measurements  
Tissue culture supernatants were centrifuged at 200 x g to eliminate cells and stored at -80oC until 
Luminex analysis. Samples were analysed in duplicates using human magnetic Luminex® screening assays 
(R&D Systems) and Luminex® 100™ or 200™  (Qiagen) Luminex analyzer instruments, according to 
manufacturers’ instructions. Five-parameter logistic standard curves were generated and analyte 
concentrations within each sample were interpolated (taking into account the dilution factor) using the 
Bio-Plex Manager™ Software (Bio-Rad).  
 
Patient samples 
Samples were obtained with the understanding and the informed consent of each participant and 
approved by local and regional ethical committees (CEIC La Paz Hospital, CEI Infanta Sofía Hospital and 
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CSIC Local Ethical Committee). Peripheral blood was obtained from a cohort of bladder cancer patients 
(Ta/T1 G3 or CIS, mean age 72.8) receiving BCG instillations, at different times during treatment at 
Hospital Infanta Sofía (Madrid, Spain). As control, bladder cancer patients (Ta/T1 G2, mean age 70.1) 
receiving mitomycin-C instillations were also recruited. 100 µl of whole blood were stained using directly 
conjugated antibodies and analysed by flow cytometry for the expression of CD56 and CD16 using a 
Gallios Flow cytometer and Kaluza software. Data processing was performed using an algorithm created 
to compile information for further statistical analysis using the GraphPad Prism 6 package. Unless 
otherwise indicated, statistical significance was assessed using multiple t-tests and corrected for multiple 
comparisons using the Sidak-Bonferroni method. 
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Figure legends  
 
Figure 1. Expansion and activation of an anti-tumoral CD56bright NK cell population. 
PBMCs from healthy donors were incubated with or without BCG at a 1:50 ratio (viable bacteria to 
PBMC). At day 7, cells in suspension were recovered from the co-culture, centrifuged and analysed.  A. 
Flow cytometry of PBMCs at day 7 showing the percentage of NK cells as CD56bright and CD56dim 
populations. A representative experiment is shown. B. Statistical analysis. The plot represents the 
comparison using a Student t-test of the percentage of CD56bright within total NK cells in PBMCs from 29 
different donors stimulated or not with BCG (**** means significant, p<0.0001). C. Degranulation of NK 
cells against bladder cancer cells (T24, UM-UC-3, RT-112, RT4, J82, SW780) and positive control (K562 
cells) was measured by analysing surface LAMP-1 (CD107a) within the CD3-CD56+ regions; CD56bright and 
CD56dim were analysed separately. The distribution and average of degranulation percentages obtained 
from, at least, 9 assays are represented. Statistical analysis was performed using one-way ANOVA (*, 
p<0.05; ****, p<0.0001). D. Activation markers. Surface expression of CD69 (left) and CD25 (right) on NK 
cells was analysed by flow cytometry each day of the week of treatment with BCG in 3 independent 
experiments. In the CD56bright, the MFI represented for CD25 corresponds to nearly 100% of the 
population, while the MFI for CD69 corresponds to 72±14% (see text). Statistical analysis was performed 
using Two-way ANOVA (*, p<0.05; ***, p<0.001). E and F. Proliferation assays. PBMCs from healthy 
donors were labelled with CellTraceTM Violet prior to the incubation with or without BCG. Proliferation 
was analysed evaluating the amount of dye per cell by flow cytometry in the CD3-CD56bright and CD3-
CD56dim regions (E) and the percentage of cells that had proliferated within CD3-CD56bright, CD3-CD56dim, 
CD3+ and CD3+CD56+ regions (F) in 4 independent experiments. Statistical analysis was performed using 
two-way ANOVA (*, p<0.05; **, p<0.01). 
 
Figure 2. BCG-stimulated CD56bright NK cells express CD16, KIRhi, CD57 and CD94hi  
PBMCs from healthy donors were incubated for 1 week with or without BCG at a 1:50 ratio. Samples 
were analysed by flow cytometry at day 7. A. Expansion of the CD56bright subset and NK receptor 
phenotyping, gating inside the CD3-CD56+ region, corresponding to a representative donor. B. 
Percentages of NK receptors in the CD56bright and CD56dim populations. C. Mean fluorescence intensity of 
NK receptors in the CD56bright and CD56dim populations. B and C show the statistical analysis of the 
phenotypes obtained in 5 independent experiments using a Student t-test (* means significant, p<0.05; 
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**, p<0.01; ***, p<0.001). For comparison, an example of normal peripheral blood NK receptor values is 
shown in Supplementary Figure 3. 
 
Figure 3. BCG-stimulated CD56bright NK cells originate mainly from CD56dim cells. 
A. PBMCs from healthy donors were labelled with directly conjugated antibodies. CD3- CD56bright and 
CD3-CD56dim populations were eliminated by cell sorting and the resulting PBMC population was 
analysed by flow cytometry. B. The cells obtained in A were incubated for 1 week with or without BCG at 
a 1:50 ratio. Samples were analysed by flow cytometry at day 7. Figure shows the expansion of the 
CD56bright subset and NK receptor phenotyping in a representative donor. This experiment was repeated 
3 times. 
 
Figure 4. BCG-activated CD56bright NK cells capacities.  
PBMCs from healthy donors were incubated with or without BCG at a 1:50 ratio. Perforin (A) and 
granzyme B (B) content of the different NK cell subpopulations were analysed by flow cytometry at day 
7. The figures show the average and distribution of the mean fluorescence intensity obtained in each 
CD3-CD56+ subpopulation as indicated. The MFIs represented corresponds to nearly 100 % of the 
population. Comparison of the results obtained from untreated vs BCG-treated cultures, from a total of 8 
independent experiments, was performed using a Student t-test (* means significant, p<0.05; n.s., non-
significant). C. IFN-γ release upon target recognition. NK cells (CD3-CD56+), CD56bright and CD56dim 
subpopulations, were analysed for their ability to release IFN-γ after being co-cultured with BCG for 3 
(upper panels) or 7 days (bottom panels) and further incubated with the indicated target cells. Statistical 
analysis of 3-5 independent experiments were done using a Student t-test (*, p<0.05; **, p<0.01). D. 
ADCC. After one week in culture with BCG, CD56bright and CD56dim NK cell subpopulations were analysed 
for their capacity to perform ADCC against Raji cells pre-incubated with rituximab. Figure shows the 
results obtained from 6 independent experiments. Statistical analysis was performed using a 2-way 
ANOVA (*, p<0.05, **, p<0.01, p<0.05; ***, p<0.001, ****, p<0.0001). 
 
Figure 5. Anti-tumour CD56bright induction by BCG requires soluble factors 
CD56bright expansion (A) and degranulation (B) in experiments using BCG-conditioned media. PBMCs from 
healthy donors were supplemented as indicated with supernatant (SN) from a previous 7-day co-culture 
of PBMCs with BCG (BCG-conditioned SN) or from a 7-day culture of PBMCs alone (untreated SN). For 
reference, untreated and BCG-treated PBMCs were used. At day 7, cells were recovered and the 
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percentage of CD56bright NK cells was analysed by flow cytometry (A) or degranulation assays against 
bladder cancer cells were performed (B). As positive control for the assay, NK cell activity against K562 
cells was analysed (not shown). Statistical analysis of 4 independent experiments was performed using 
Student t-test (* means significant, p<0.05; n.s., not significant). CD56bright expansion (C) and phenotype 
(D), after NK cell subpopulation sorting and incubation using Transwell.  PBMCs from 3 healthy donors 
(two donors shown) were labelled with directly conjugated antibodies. CD3- CD56bright and CD3-CD56dim 
populations were separated by cell sorting and set in the upper chamber of a transwell. In the lower 
chamber, total PBMCs were incubated for 7 days in the presence or absence of BCG. After this time, NK 
cells subpopulations from the upper chamber were analysed by flow cytometry.  
 
Figure 6. Soluble factors released by PBMCs in the presence of BCG during one week of co-incubation. 
PBMCs from three healthy donors were incubated with or without BCG at a 1:50 ratio. Daily, 
supernatants were recovered, centrifuged to eliminate cells and bacteria, and used to determine the 
content in soluble factors by Luminex. NK cells from the different cultures were analysed at day 7 to 
control the expansion and capacity to respond by degranulation against different bladder cell lines 
(Supplementary figure 4). A. Quantitation of the indicated cytokines or chemokines contained in the 
supernatants during 7 days. B. Summary of the cytokines and chemokines released by PBMCs co-
cultured in vitro with or without BCG. Bold and italics: soluble factors detected at ≥ 1000 pg/ml; 
Underlined: condition in which the concentration was higher, when a soluble factor was detected in 
cultures with or without BCG. 
 
 
Figure 7. Analysis of blood samples obtained from bladder cancer patients treated with BCG. 
A. Schematic representation of sample collection. A cohort of bladder cancer patients (Ta/T1G3 or CIS, 
mean age 72.8 years old) receiving intravesical BCG instillations was recruited. During the first cycle, 
patients received one weekly instillation for 6 weeks (indicated by arrows). After a three-month rest 
period, they received a second cycle of two weekly instillations and they continued this treatment for up 
to three years.  Samples were obtained just before receiving an instillation at the time points indicated 
with a circle. Therefore, the sample obtained just before the first instillation of the first cycle is the basal 
level. Remaining samples were obtained a week after the patient received an instillation or after the 
three-month rest period. B and C. NK cell analysis of patient PBMCs. Whole blood was analysed by 
multiparametric flow cytometry. Gating was performed by selecting lymphocytes by FSC/SSC and the 
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percentage of total NK cells (B) as well as CD56bright (C) on total NK cells was obtained. The figure 
represents the average and standard deviation of the CD56 percentages of all samples obtained for each 
patient along the treatment. D. CD16. The MFI of CD16 was determined in the different NK cell 
populations of the patients at different times (12 time points for BCG-treated patients; 4 time points for 
mitomycin C-treated patients). CD16 MFI ranged between 0.6 and 8 in CD56bright, and 9.8 and 40.3 for 
CD56dim within these patients cohorts (data not shown). The values of the CD16 MFI from the initial 
(before starting the treatment) and final samples (12 months for BCG, 3 months for mitomycin C) were 
normalised for comparison and statistical analysis. The significance of the variation between the initial 
and final sample was analysed by t-test using the Sidak-Bonferroni method (* means significant, p<0.05). 
 
 
Supplementary figure 1. Activating receptors involved in the recognition of bladder cancer cells by NK 
cells from BCG-activated PBMCs. The effect of activating receptor blockade was studied in degranulation 
experiments measuring surface LAMP-1 (CD107a) by flow cytometry. NK cells were pre-incubated with 
antibodies against the indicated receptors before the co-incubation with bladder cancer targets for 2 
hours at an E:T ratio of 1:2. CD56bright and CD56dim NK cells were analysed separately. 
 
Supplementary figure 2. Survival of lymphocytes during one week of co-culture with BCG. PBMCs were 
co-incubated with BCG and recovered at day 7 for analysis with Annexin V/7AAD. The panel shows one 
representative of 5 experiments. Left: CD56bright and CD56dim NK cell survival analysis. The number 
indicated in the upper corner of each quadrant corresponds to the percentage of dead cells (Annexin 
V+/7AAD+) 
 
Supplementary figure 3. Typical NK receptor phenotype in PBMCs of healthy donors. PBMCs from a 
healthy donor were isolated and analysed by flow cytometry using the indicated markers. 
 
Supplementary Figure 4. CD158a and CD158b show a similar increase in BCG-stimulated CD56bright NK 
cells. PBMCs from healthy donors were incubated for 1 week with or without BCG at a 1:50 ratio. 
Samples were analysed by flow cytometry at day 7. The statistical analysis of the phenotypes obtained in 
4 independent experiments using a Student t-test (* means significant, p<0.05; **, p<0.01; ***, p<0.001) 
is represented in the different types of graphs. A. Percentages of KIR2D (CD158a and CD158b) NK 
receptors in the CD56bright and CD56dim populations. B. Mean fluorescence intensity (MFI) of KIR2D 
26 
 
(CD158a and CD158b) in the positive populations of CD56bright and CD56dim. C. Percentages of KIR3D 
(NKB1/DX9) NK receptors in the CD56bright and CD56dim populations. D. The percentage of CD158-positive 
cells is enriched in BCG-activated CD56brightCD16+CD57+. E. CD57 expression was increased in CD16+ 
versus CD16- BCG-stimulated CD56bright cells. In A-D symbols represent different donors. 
Different amounts of the individual KIR molecules are expressed in different donors at different levels in 
basal conditions, probably dependent on the individual haplotype. For example, one of the donors 
included in these data did not express any CD158a, but showed a high percentage of CD158b. 
 
Supplementary figure 5. CD56bright expansion and degranulation against different bladder cell lines after 
BCG co-culture of the same PBMCs used to determine the soluble factors released into supernatants 
during one week (experiment shown in Figure 6). PBMCs from 3 healthy donors were incubated with or 
without BCG at a 1:50 ratio (viable bacteria to PBMC). At day 7, cells in suspension were recovered from 
the co-culture, centrifuged and analysed.  Left panels (for each donor): Flow cytometry of PBMCs at day 
7 showing the percentage of NK cells as CD56bright and CD56dim populations. Right panels (for each donor): 
degranulation of NK cells against bladder cancer cells (J82, T24, UM-UC-3) was measured by analysing 
surface LAMP-1 (CD107a) within the CD56bright region. 
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Supplementary Table 1. List of antibodies used  
Ab Fluorochrome Clone Supplier 
CD3 CF UCHT-1 Immunostep 
CD3 FITC OKT3 Biolegend 
CD16 PE/Cy7 3G8 Biolegend 
CD25 PB BC96 Biolegend 
CD56 PE HCD56 Biolegend 
CD56 PE/Cy5 NKH-1 Immunotech 
CD57 FITC HNK-1 BD FACS™ 
CD69 APC/Cy7 FN50 Biolegend 
CD94 APC DX22 Biolegend 
CD107a/LAMP1 APC H4A3 Biolegend 
CD158a PE EB6 Beckman Coulter 
CD158b PE GL183 Beckman Coulter 
NKB1 PE 36105x Pharmingen 
Granzyme B APC/Cy7 GB11 Mabtech 
IFNγ PE 4S.B3 Biolegend 
Perforin APC/Cy7 dG9 Biolegend 
7-AAD     Sigma 
Annexin V PE   Immunostep 
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NK receptor phenotype in PBMC of healthy donors 
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E. CD57+ in subsets of BCG-
activated CD56bright cells 
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